Wave Life Sciences Shareholders Approve 11 Million Additional Shares For Stock Awards

The equity-plan expansion drew 22,936,097 opposing votes; shareholders separately endorsed executive pay.

Share
Wave Life Sciences Shareholders Approve 11 Million Additional Shares For Stock Awards

Wave Life Sciences, which develops RNA medicines, won shareholder approval Thursday to add 11 million shares to its existing stock-award pool. The company reported the vote in an SEC filing Wednesday.

More Shares For Awards

The amendment expands the number of common shares authorized for awards under Wave's equity incentive plan. Shareholders backed it by 119,800,336 votes to 22,936,097, while 82,514 votes abstained.

The approval increases the shares available for stock-based awards. Authorization is the step shareholders approved Thursday; the vote concerns the plan's capacity to issue awards.

Shareholders representing 166,197,073 shares participated in person or through proxies, accounting for 84% of shares eligible to vote. Wave had 197,228,058 common shares outstanding and eligible for the meeting.

Pay Wins Broader Support

Executive pay received 133,800,043 votes in favor and 8,866,314 against. Another 152,590 votes abstained. The endorsement was advisory and nonbinding.

All nine existing directors were re-elected: Paul B. Bolno, Mark H.N. Corrigan, Christian Henry, Peter Kolchinsky, Adrian Rawcliffe, Ken Takanashi, Aik Na Tan, Gregory L. Verdine and Heidi L. Wagner.

Shareholders also ratified KPMG as Wave's independent auditor for the year ending December 31, 2026. That proposal received 165,767,838 supporting votes, 338,795 opposing votes and 90,440 abstentions.

RNA Drugs Across Inherited Diseases

Wave is a clinical-stage biotechnology company whose medicines use short strands of genetic material to target RNA. Its PRISM platform designs those drugs.

Its lead programs include WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, a rare inherited condition that damages the lungs and liver. WVE-008 targets a genetic form of liver disease.

Wave also has clinical programs for Duchenne muscular dystrophy and Huntington's disease, alongside several programs still in preclinical development. GSK collaborates with Wave on target-validation programs and prepays all of Wave's costs and expenses for that work.

The company produces oligonucleotides—the short genetic strands used in its medicines—at its Lexington, Massachusetts facility and uses contract manufacturers.

The re-elected directors' terms extend to Wave's 2027 annual meeting and until their successors are elected and qualified.

Sources

More on Wave Life Sciences

All Wave Life Sciences (WVE) coverage →